Healthcare News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Marie Mazur appointed chair of PharmaJet board

PharmaJet named Marie Mazur, PharmD, chairwoman of the board, replacing Ron Lowy, who had chaired the board since 2011. “Marie’s experience and leadership will be of great benefit for our company as we are accelerating...

June 6, 2023

Executive Moves

Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) appointed Kaouthar Lbiati, M.D., as an independent director. Dr. Lbiati received a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a...

June 6, 2023

Developments

Check-Cap reviewing strategic alternatives

Check-Cap (NASDAQ:CHEK) is exploring strategic alternatives, such as the sale of all or part of the company, licensing, merger or reverse merger, and has retained Ladenburg Thalmann as an advisor to the company. Check...

June 6, 2023

Developments

iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline

iBio (NYSEA:IBIO) expanded its AI-powered technology stack with the launch of EngageTx, a proprietary T-cell engager antibody panel designed for developing bispecific antibodies for immuno-oncology applications. Through...

June 6, 2023

Executive Moves

Perimeter Medical names Adrian Mendes as CEO; appoints Dr. Josh Vose to board

The board of Perimeter Medical Imaging AI (TSXV:PINK; OTC:PYNKF; FSE:4PC) appointed Adrian Mendes as CEO, effective immediately, succeeding Jeremy Sobotta, who has resigned for personal reasons, effective June 15, 2023...

June 5, 2023

Markets

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...

June 5, 2023

Developments

Synlogic initiates pivotal study for phenylketonuria

Synlogic (NASDAQ:SYBX) initiated Synpheny-3, a global, Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU), a rare inherited disorder that causes an amino...

June 5, 2023

Developments

Jazz, Zymeworks present positive pivotal data in BTC

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific...

June 5, 2023

Developments

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that, with sponsorship and support from multiple physician specialty societies, it has received from the American Medical Association (AMA) three new Current Procedural...

June 2, 2023

Executive Moves

Ondine Biomedical names Simon Sinclair as CMO

Ondine Biomedical (LON:OBI) appointed Simon Sinclair, M.D., Ph.D., as chief medical officer, as the company prepares to start a U.S. Phase 3 trial of its nasal photodisinfection technology. Dr. Sinclair has more than 20...

June 1, 2023

Developments

Vistagen presents Phase 3 data for SAD

Vistagen (NASDAQ:VTGN) presented positive safety and exploratory efficacy data at the American Society for Clinical Psychopharmacology annual meeting in Miami from its large Phase 3 open-label study of fasedienol nasal...

June 1, 2023

Developments

Ionis posts late-stage clinical progress in HAE

Ionis Pharmaceuticals (NASDAQ:IONS) reported positive clinical progress with donidalorsen, its late-stage investigational prophylactic therapy for hereditary angioedema (HAE). Topline two-year open-label extension (OLE)...

June 1, 2023

Marie Mazur appointed chair of PharmaJet board

Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director

Check-Cap reviewing strategic alternatives

iBio expands tech stack with EngageTx; adds TROP-2 bispecific to pipeline

Perimeter Medical names Adrian Mendes as CEO; appoints Dr. Josh Vose to board

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Synlogic initiates pivotal study for phenylketonuria

Jazz, Zymeworks present positive pivotal data in BTC

AMA unveils new CPT Category 1 codes for Profound Medical’s TULSA-PRO

Ondine Biomedical names Simon Sinclair as CMO

Vistagen presents Phase 3 data for SAD

Ionis posts late-stage clinical progress in HAE

General

More